Early Phase 2 Clinical Trial of E6011 in Patients With Active Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2019
Price : $35 *
At a glance
- Drugs Quetmolimab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors EA Pharma
- 08 Mar 2019 Planned End Date changed from 1 Sep 2021 to 1 Dec 2021.
- 13 Nov 2018 Status changed from not yet recruiting to recruiting.
- 02 Nov 2018 New trial record